Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
LUCD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)942.77K
Market Cap
$148.61M
Enterprise Value$164.69M
Total Cash (Recent Filing)$31.12M
Total Debt (Recent Filing)$27.55M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Nov 17, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding108,477,490
10 Day Avg. Volume1,350,870
30 Day Avg. Volume942,771
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue37.77
Enterprise Value/Gross Profit-58.71
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
$2.58Price Target Upside111.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical ValidationThe CAC panelists highlighted that EsoGuard is effective in its purpose as a rule-out test for Barrett's esophagus with high clinical validity and utility.
Market PotentialThe Medicare price of $1,938 per test suggests a significant total addressable market of around $60 billion.
Medicare CoverageAchieving Medicare MolDX coverage is seen as a major potential catalyst for LUCD shares that would enable LUCD to be paid for a much larger portion of its testing volume and accelerate its revenue ramp.
Bears Say
Financial PerformanceQ2 loss from operations of -$11.4M roughly matched the analyst's estimate, indicating ongoing financial challenges.
Medicare Coverage DelaysThe Medicare coverage determination is taking slightly longer than expected, leading to lowered revenue estimates.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.73 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Lucid Diagnostics’s market cap is $148.61M.
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Nov 17, 2025 which is in 69 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Aug 13, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.014.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -0.1.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 108,477,490 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went down -2%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.58 (111.48% Upside)
$2.58 (111.48% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 29.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $101.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
76.31%
12-Months-Change
Fundamentals
Return on Equity
-463.56%
Trailing 12-Months
Asset Growth
13.36%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics (LUCD) is a medical diagnostics company focused on the development and commercialization of diagnostic tests for the early detection of esophageal precancer and cancer. The company's core product is the EsoGuard Esophageal DNA Test, which is designed to detect genetic abnormalities indicative of esophageal cancer and precancerous conditions, such as Barrett's Esophagus, using a non-invasive method. Lucid Diagnostics operates in the healthcare sector, specifically within the molecular diagnostics and gastrointestinal health fields.
LUCD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, including significant revenue growth, successful partnerships, and progress toward Medicare coverage. However, challenges remain in terms of revenue recognition and high operational costs. The sentiment is cautiously optimistic with a focus on achieving Medicare coverage as a key milestone.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$2.58
▲(111.48% Upside)
Technical Analysis
Ownership Overview
2.75% Insiders
1.05% Mutual Funds
4.71% Other Institutional Investors
86.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---